Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Harvard Business School
Cipla
US Department of Justice
UBS
Fuji
Fish and Richardson
Citi

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,585,911

« Back to Dashboard

Title:Sachet formulation for amine polymers
Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
Inventor(s): Bhagat; Hitesh R. (Wayland, MA), Goldberg; Jeffrey M. (Framingham, MA)
Assignee: GENZYME CORPORATION (Cambridge, MA)
Filing Date:Jun 25, 2015
Application Number:14/750,459
Claims:1. A method of treating a patient suffering from hyperphosphatemia, comprising: administering to the patient a therapeutically effective amount of powder formulation comprising a mixture of: a) a pharmaceutically acceptable anionic stabilizer comprising an esterified alginate; b) carbonate salt of sevelamer mixed with the anionic stabilizer; and c) sodium chloride; wherein: i) the ratio of the anionic stabilizer to sevelamer carbonate is 0.005-1:1; and ii) the only pharmaceutically active ingredient in the powder is the sevelamer carbonate.

2. The method of treating of claim 1, wherein the esterified alginate is a propylene glycol alginate.

3. The method of treating of claim 1, wherein the amount of the sevelamer carbonate is 800 mg on an anhydrous basis.

4. The method of treating of claim 1, wherein the amount of the sevelamer carbonate is 2.4 g on an anhydrous basis.

5. The method of treating of claim 1, wherein the chloride of the sodium chloride is present in a range of between 0.01-2 wt. % relative to the combined weights of the sevelamer carbonate and the sodium chloride.

6. The method of treating of claim 1, wherein the chloride of the sodium chloride is present in a range of between 0.05-1 wt. % relative to the combined weights of the sevelamer carbonate and the sodium chloride.

7. The method of treating of claim 1, wherein the chloride of the sodium chloride is present in a range of between 0.08-0.5 wt. % relative to the combined weights of the sevelamer carbonate and the sodium chloride.

8. The method of treating of claim 1, wherein the powder is uncapsulated and free-flowing, and wherein the powder contains less than 5 wt % of particles having a particle size more than 300 microns and less than 5 wt % of particles having a particle size less than 10 microns.

9. The method of treating of claim 1, wherein the powder formulation further comprises one or more of a pharmaceutically acceptable flavoring agent, sweetener, or coloring agent.

10. The method of treating of claim 9, wherein the powder formulation further comprises a pharmaceutically acceptable flavoring agent.

11. The method of treating of claim 10, wherein the pharmaceutically acceptable flavoring agent includes at least one member selected from the group consisting of grape, cherry, peppermint, menthol, vanilla flavor, orange vanilla flavor, lemon flavor, spearmint, wintergreen, cinnamon, and menthone flavors.

12. The method of treating of claim 11, wherein the at least one pharmaceutically acceptable flavoring agent is lemon flavor.

13. The method of treating of claim 9, wherein the powder formulation further comprises a pharmaceutically acceptable sweetener.

14. The method of treating of claim 13, wherein the pharmaceutically acceptable sweetener includes at least one member selected from the group consisting of sucralose, sucrose, xylose, mannitol, maltitol, maltol, sorbitol and xylitol.

15. The method of treating of claim 14, wherein the at least one pharmaceutically acceptable sweetener is sucralose.

16. The method of treating of claim 9, wherein the powder formulation further comprises a pharmaceutically acceptable coloring agent.

17. The method of treating of claim 16, wherein the pharmaceutically acceptable coloring agent is yellow iron oxide.

18. The method of treating of claim 1, wherein the subject has a serum phosphate level of greater than about 4.5 mg/dL.

19. The method of treating of claim 1, wherein the therapeutically effective amount of the powder formulation is orally administered to the patient.

20. The method of treating of claim 1, wherein the powder formulation is packaged in a unit-dose container or a multi-dose container.

21. The method of treating of claim 20, wherein the unit-dose container or multi-dose container is a tub or sachet.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
Johnson and Johnson
Chubb
Argus Health
UBS
US Department of Justice
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.